Axsome Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $259,691 | $218,375 | $191,203 | $195,999 |
Gross Profit | 241,887 | 204,811 | 176,478 | 183,670 |
EBITDA | -11,068 | -46,759 | -60,990 | -24,683 |
EBIT | -11,068 | -49,646 | -63,357 | -26,957 |
Net Income | -12,877 | -51,314 | -64,542 | -28,559 |
Net Change In Cash | 259,691 | 218,375 | 191,203 | 195,999 |
Free Cash Flow | -9,666 | -32,831 | -20,821 | -18,724 |
Cash | 313,859 | 319,850 | 305,106 | 322,933 |
Basic Shares | 52,445 | 51,500 | 51,198 | 50,631 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $638,496 | $385,693 | $270,600 | $50,037 |
Gross Profit | 591,018 | 352,390 | 244,535 | 44,839 |
EBITDA | -168,083 | -272,604 | -224,991 | -175,397 |
EBIT | -177,147 | -280,562 | -231,825 | -179,799 |
Net Income | -183,174 | -287,216 | -239,238 | -187,134 |
Net Change In Cash | 638,496 | 385,693 | 270,600 | 50,037 |
Free Cash Flow | -93,885 | -128,680 | -145,662 | -117,213 |
Cash | 322,933 | 315,353 | 386,193 | 200,842 |
Basic Shares | 49,747 | 47,914 | 45,425 | 40,655 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | -$0.25 |
2026-06-30 | -$0.99 |
2026-03-31 | -$1.26 |
2025-12-31 | -$0.56 |